The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes

Keyphrases

• Endothelial Dysfunction 100%
• Diabetes 100%
• Poly(ADP-ribose) Polymerase 100%
• Myocardial Dysfunction 100%
• Cardiac Dysfunction 50%
• Beneficial Effects 33%
• PARP Inhibitor (PARPi) 33%
• Streptozotocin-induced 33%
• High Incidence 16%
• Vascular Reactivity 16%
• Hyperglycemia 16%
• Diabetic 16%
• Vascular Complications 16%
• Thoracic Aorta 16%
• Neuropathy 16%
• Myocardial Infarction 16%
• Nephropathy 16%
• Retinopathy 16%
• Endothelium-dependent Vasodilation 16%
• Poly (ADP-ribose) Polymerase Inhibition 16%
• Diabetic Cardiomyopathy 16%
• Severe Hyperglycemia 16%
• PJ34 16%
• Patients with Diabetes 16%
• Cardiovascular Complications 16%
• Diabetic Model 16%
• Non-obese Diabetic 16%
• Hypertension Risk 16%
• Diastolic Dysfunction 16%
• Induced Models 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 100%
• Endothelial Dysfunction 100%
• Hyperglycemia 33%
• Streptozotocin 33%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 33%
• Mouse 16%
• Diabetes Mellitus 16%
• Kidney Disease 16%
• Cardiovascular Disease 16%
• Neuropathy 16%
• Heart Infarction 16%
• Retinopathy 16%
• Diabetic Cardiomyopathy 16%
• N (5,6 Dihydro 6 Oxo 2 Phenanthridinyl) 2 Dimethylaminoacetamide 16%
• Diastolic Dysfunction 16%